Blood Cancer Drugs Market Worth $55.6 Billion by 2025 | Industry Participant: Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Roche Holding AG, Celgene Corporation and others.
The global blood cancer drugs market is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report ‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’ provides insights on the current market scenario and the future prospects.Request for sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-sample
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
The global blood cancer drugs market is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
Browse summary of this report with TOC @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market
On the basis of treatment approaches the global blood cancer drugs market is further segmented into Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic. Due to availability of variety of chemotherapeutic agent in the market chemotherapeutic drugs are expected to hold the higher share in blood cancer drugs market. Moreover, their effectiveness for the treatment of blood cancer and increasing number of cancer patients globally has garnered more demand for chemotherapeutic drugs throughout the world.
Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.
The leading companies operating in this industry include Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer, Inc., AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC, Merck & Co., Inc., and Eli Lily & Co. among others.
Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.
Inquire before-buying @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/inquire-before-buying
Polaris Market Research has segmented the global blood cancer drugs market on the basis of type, drugs, treatment approaches and region:
Blood cancer drugs market Size and Forecast, 2017-2025 by Blood Cancer Type
• Lymphoma
o Hodgkin Lymphoma
o Non-Hodgkin Lymphoma
B-cell Lymphoma
o Diffuse Large B-Cell Lymphoma
o Mantle Cell Lymphoma
o Burkitt Lymphoma
o Central Nervous System Lymphoma
T-cell Lymphoma
o Precursor T-Lymphoblastic Lymphoma
o Peripheral T-Lymphoma
• Leukemia
o Acute Myeloid Leukemia
o Chronic Myeloid Leukemia
o Acute Lymphoblastic Leukemia
o Chronic Lymphocytic Leukemia
• Myeloma
o Multiple Myeloma
Blood cancer drugs market Size and Forecast, 2017-2025 by Drugs
• Rituaxan/Mabthera (Rituximab)
• Gleevac/Glivec (Imatinib)
• Revlimid (Lenalidomide)
• Velcade (Bortezomib)
• Tasigna (Nilotinib)
• Pomalyst (Pomalidomide)
• Vidaza (Azacitidine)
• Kyprolis (Carfilzomib)
• Adcetris (Brentuximab Vedotin)
• Others
Blood cancer drugs market Size and Forecast, 2017-2025 by Treatment Approaches
• Chemotherapeutic
• mAbs/Targeted Therapies
• Immunotherapeutic
Blood cancer drugs market Size and Forecast, 2017-2025 by Region
• North America
o U.S.
o Canada
• Europe
o Germany
o UK
o France
• Asia Pacific
o China
o Japan
o India
• Latin America
o Brazil
o Mexico
• Middle East & Africa
Check for discount @ https://www.polarismarketresearch.com/industry-analysis/global-blood-cancer-drugs-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide our customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to our customers.
Contact us
Mr. Rohit
Corporate Sales, USA
Polaris Market Research
Phone: 1-646-568-9980
Email: sales@polarismarketresearch.com
Web: www.polarismarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Blood Cancer Drugs Market Worth $55.6 Billion by 2025 | Industry Participant: Johnson & Johnson Inc., Amgen Inc., Bayer AG., Pfizer Inc., Eli Lily & Co., AstraZeneca, AbbVie Inc., Roche Holding AG, Celgene Corporation and others. here
News-ID: 1699548 • Views: …
More Releases from Polaris Market Research & Consulting
U.S. Healthcare Discount Plan Market is projected to grow to US$ 4.57 Billion by …
Polaris Market Research has recently published its latest analysis titled "U.S. Healthcare Discount Plan Market." The report reveals that the market for U.S. healthcare discount plans was valued at USD 1.89 billion in 2023. The market is projected to grow to USD 4.57 billion by 2032, exhibiting a CAGR of 10.4% during the forecast period.
The ongoing escalation in healthcare prices has been a notable propeller of the market. AS…
Laser Capture Microdissection Market is projected to grow to US$ 397.74 Million …
Polaris Market Research's latest report, titled " Laser Capture Microdissection Market," 2024-2032. The report covers key success factors, market performance, risk factors, project costs and economics, expected ROI, and profit margins. The global market was valued at USD 167.04 million in 2023 and is expected to grow to USD 397.74 million by 2032 at a CAGR of 10.1% during the forecast period.
What is Laser Capture Microdissection?
Laser capture microdissection under direct…
Ready-To-Drink Cocktails Market Projections to Show Global Growth to US$ 3,066.5 …
The ready-to-drink cocktails market is growing as market demand increases, boasting a 13.20% growth rate over the forecast period. Market researchers anticipate an estimated value of USD 3,066.52 million by 2032. The value is USD 1002.29 million in 2023. The ready-to-drink cocktail trend and shifting consumer lifestyle choices to improve health are the main factors driving the industry's growth. Additionally, due to their ongoing accessibility, customers are being encouraged to…
Artificial Intelligence in Precision Medicine Market Predicted to Grow to USD 26 …
According to Polaris Market Research's latest research report titled, "Artificial Intelligence in Precision Medicine Market by Technology (Deep Learning, Querying Method, Natural Language Processing, and Context Aware Processing), Component, Therapeutic Application, Region - Global Forecast to 2032", the market size was valued at USD 1.26 billion in 2022 and is projected to grow to USD 26.24 billion by 2032. The industry is projected to exhibit a CAGR of 35.5% during…
More Releases for Lymphoma
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
Overview Of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Re …
Researchmoz added Most up-to-date research on "Overview Of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" to its huge collection of research reports.
GlobalData's clinical trial report, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" provides an overview of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). Report…
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.
Hodgkin disease is a cancer of the lymphatic system. It…
Pipeline Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market Review, H2 2017
"The Report Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape.
Hodgkin disease is a cancer of the lymphatic system. It…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…